Dry Age-related Macular Degeneration Clinical Trial
Official title:
HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).
This is a Phase 2, open-label, outcomes-assessor masked, multicentre, randomised, controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD. The trial includes a screening period of up to 8 weeks and a 96-week study period. Subjects will be randomised to one of two groups; GT005 or the untreated control group. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03046407 -
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04339764 -
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05536752 -
QA102 Phase II Study in Subjects With Dry AMD
|
Phase 2 | |
| Recruiting |
NCT06351605 -
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)
|
||
| Active, not recruiting |
NCT04065490 -
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
|
N/A | |
| Recruiting |
NCT06229665 -
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
|
Phase 2/Phase 3 | |
| Completed |
NCT01002950 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
|
Phase 2 | |
| Active, not recruiting |
NCT03333954 -
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
|
N/A | |
| Completed |
NCT05667688 -
Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85
|
Phase 1 | |
| Completed |
NCT01379560 -
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT03144999 -
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
|
Phase 1 | |
| Withdrawn |
NCT04511936 -
Microcurrent Stimulation for Dry Age-related Macular Degeneration
|
N/A | |
| Withdrawn |
NCT04358471 -
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)
|
Phase 2 | |
| Terminated |
NCT04643886 -
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
|
Phase 2 | |
| Not yet recruiting |
NCT05418231 -
Observation of the Natural Course of Age-related Macular Degeneration
|
||
| Recruiting |
NCT00926861 -
Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD
|
N/A | |
| Active, not recruiting |
NCT04437368 -
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
|
Phase 2 | |
| Active, not recruiting |
NCT03894020 -
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
|
||
| Not yet recruiting |
NCT04875234 -
Vision Improvement for Legally Blind Dry AMD Patients
|
||
| Recruiting |
NCT02755428 -
Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases
|
Phase 1/Phase 2 |